Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Turecek

Showing results (21-30 of 91) with videos related to

Pageof 10
Sort By:
Thrombosis and Haemostasis|March 1, 2005
Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammationRosemarie A Reiter, Katalin Varadi, Peter L Turecek, et al.
Electrophoresis|April 27, 2011
Structural analysis of the recombinant therapeutic product rFVIII and its PEGylated variants using 2-D DIGEChristina Monetti, Hanspeter Rottensteiner, Herbert Gritsch, et al.
Journal of Pharmaceutical and Biomedical Analysis|July 17, 2007
Convenient high-resolution isoelectric focusing (IEF) method for the separation of alpha1-proteinase inhibitor (A1PI) isoforms in A1PI concentratesAlfred Weber, Andrea Engelmaier, Maurice C Owen, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|August 25, 2018
Issues complicating precision dosing for factor VIII prophylaxisLeonard A Valentino, Peter L Turecek, Herbert Gritsch, et al.
Journal of Blood Medicine|November 21, 2022
Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand DiseaseHerbert Gritsch, Gerald Schrenk, Nina Weinhappl, et al.
Hamostaseologie|July 28, 2020
Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with InhibitorsHans H Brackmann, Wolfgang Schramm, Johannes Oldenburg, et al.
Thrombosis and Haemostasis|February 23, 2002
Single cell analysis of factor VIII-specific T cells in hemophilic mice after treatment with human factor VIIIMaria Sasgary, Rafi U Ahmad, Hans Peter Schwarz, et al.
Histochemistry and Cell Biology|April 6, 2002
In vivo and in vitro processing of recombinant pro-von Willebrand factorPeter L Turecek, Katalin Váradi, Uwe Schlokat, et al.
Journal of Pharmaceutical and Biomedical Analysis|November 8, 2016
Selective functional activity measurement of a PEGylated protein with a modification-dependent activity assayAlfred Weber, Andrea Engelmaier, Gabriele Mohr, et al.
Pharmaceuticals (Basel, Switzerland)|July 28, 2018
Polyethylene Glycol Exposure with Antihemophilic Factor (Recombinant), PEGylated (rurioctocog alfa pegol) and Other Therapies Indicated for the Pediatric Population: History and SafetyReinhard Stidl, Michael Denne, Jimena Goldstine, et al.
Pageof 10

Showing results (21-30 of 91) with videos related to

Sort By:
Pageof 10
Thrombosis and Haemostasis|March 1, 2005
Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammationRosemarie A Reiter, Katalin Varadi, Peter L Turecek, et al.
Electrophoresis|April 27, 2011
Structural analysis of the recombinant therapeutic product rFVIII and its PEGylated variants using 2-D DIGEChristina Monetti, Hanspeter Rottensteiner, Herbert Gritsch, et al.
Journal of Pharmaceutical and Biomedical Analysis|July 17, 2007
Convenient high-resolution isoelectric focusing (IEF) method for the separation of alpha1-proteinase inhibitor (A1PI) isoforms in A1PI concentratesAlfred Weber, Andrea Engelmaier, Maurice C Owen, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|August 25, 2018
Issues complicating precision dosing for factor VIII prophylaxisLeonard A Valentino, Peter L Turecek, Herbert Gritsch, et al.
Journal of Blood Medicine|November 21, 2022
Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand DiseaseHerbert Gritsch, Gerald Schrenk, Nina Weinhappl, et al.
Hamostaseologie|July 28, 2020
Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with InhibitorsHans H Brackmann, Wolfgang Schramm, Johannes Oldenburg, et al.
Thrombosis and Haemostasis|February 23, 2002
Single cell analysis of factor VIII-specific T cells in hemophilic mice after treatment with human factor VIIIMaria Sasgary, Rafi U Ahmad, Hans Peter Schwarz, et al.
Histochemistry and Cell Biology|April 6, 2002
In vivo and in vitro processing of recombinant pro-von Willebrand factorPeter L Turecek, Katalin Váradi, Uwe Schlokat, et al.
Journal of Pharmaceutical and Biomedical Analysis|November 8, 2016
Selective functional activity measurement of a PEGylated protein with a modification-dependent activity assayAlfred Weber, Andrea Engelmaier, Gabriele Mohr, et al.
Pharmaceuticals (Basel, Switzerland)|July 28, 2018
Polyethylene Glycol Exposure with Antihemophilic Factor (Recombinant), PEGylated (rurioctocog alfa pegol) and Other Therapies Indicated for the Pediatric Population: History and SafetyReinhard Stidl, Michael Denne, Jimena Goldstine, et al.
Pageof 10